Kaposiform hemangioendothelioma

Authors

  • María del Valle Marin El Carmen Hospital, Mendoza, Argentina
  • María Clara Venturini El Carmen Hospital, Mendoza, Argentina
  • Ileana Rosalía Camardella El Carmen Hospital, Mendoza, Argentina
  • Sonia Rodríguez Saa El Carmen Hospital, Mendoza, Argentina
  • Marisa Olivares El Carmen Hospital, Mendoza, Argentina

DOI:

https://doi.org/10.47196/da.v31i2.2878

Keywords:

kaposiform hemangioendothelioma, vascular tumors

Abstract

Kaposiform hemangioendothelioma (KHE) is a locally aggressive, rare vascular tumor that affects pediatric patients. It presents as a firm and solitary tumor, erythematous-purple, located in the skin or soft tissue, that can invade adipose tissue muscle and bone. Approximately 70% of cases may be associated with the Kasabach-Merritt phenomenon, a consumptive coagulopathy that carries significant morbidity and mortality. Due to the lack of a standardized treatment, several therapeutic options have been explored, including corticosteroid therapy, sirolimus, and vincristine. We present the case of a preterm newborn patient with KHE diagnosis.

Author Biographies

María del Valle Marin, El Carmen Hospital, Mendoza, Argentina

Dermatology Resident Physician

María Clara Venturini, El Carmen Hospital, Mendoza, Argentina

Dermatology Resident Physician

Ileana Rosalía Camardella, El Carmen Hospital, Mendoza, Argentina

Chief Resident of Dermatology

Sonia Rodríguez Saa, El Carmen Hospital, Mendoza, Argentina

Head of the Dermatology Service

Marisa Olivares, El Carmen Hospital, Mendoza, Argentina

Head of the Pathological Anatomy Service

References

I. Putra J, Gupta A. Kaposiform hemangioendothelioma: a review with emphasis on histological differential diagnosis. Pathology. 2017;49:356-362.

II. Croteau SE, Liang MG, Kozakewich HP, Alomari AE, et ál. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013;162:142-147.

III. Drolet B, Trenor C, Brandao L, Chiu Y, et ál. Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma. J Pediatr. 2013;163:285-291.

IV. Peng S, Yang K, Xu Z, Chen S, et ál. Vincristine and sirolimus in the treatment of kaposiform hemangioendothelioma. J Paediatr Child H. 2019;55:1119-24.

V. Enjolras O, Mulliken JB, Wassef M, Frieden IJ, et ál. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol. 2000;42:225-235.

VI. International Society for the Study of Vascular Anomalies (ISSVA). Classification of vascular anomalies 2018. ISSVA; 2018. Disponible en: https://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf.

VII. Gong X, Ying H, Zhang Z, Wang L, et ál. Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angioma. J Dermatol. 2019; 46:835-842.

VIII. Rodríguez V, Lee A, Witman PM, Anderson PA. Kasabach-Merritt Phenomenon. J Pediatr Hematol Oncol. 2009;31:522-526.

IX. Wananukul S, Nuchprayoon I, Seksarn P. Treatment of Kasabach-Merritt syndrome: a stepwise regimen of prednisolone, dipyridamole, and interferon. Int J Dermatol. 2003;42:741-748.

X. Yao W, Li K, Wang Z, Pei J, et ál. Comparison of corticosteroid and vincristine in treating kaposiform hemangioendothelioma and tufted angioma. A systematic review and meta-analysis. Eur J Pediatr Surg. 2019;29:401-407.

Published

2025-08-01

Issue

Section

Clinical Cases